Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty

被引:12
作者
Colwell, Clifford W., Jr. [1 ]
Hardwick, Mary E. [1 ]
机构
[1] Scripps Clin, Shiley Ctr Orthopaed Res & Educ, La Jolla, CA 92037 USA
关键词
D O I
10.1097/01.blo.0000238826.63648.c5
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Low-molecular-weight heparin has been studied extensively in total knee arthroplasty (TKA) and provides highly effective and safe prophylaxis against deep venous thrombosis (DVT). Low-molecular-weight heparin received the highest rating (A1) in the American College of Chest Physicians recommendations for DVT prophylaxis after elective TKA. Prevalence of DVT with low-molecular-weight heparin prophylaxis was 33% in TKA data pooled from six randomized studies, with a proximal DVT rate of 7.1%. A metaanalysis reported a 2.4% rate of major bleeding with low-molecular-weight heparin.(2) Low-molecular-weight heparin, given by subcutaneous injection, can be started before surgery or after surgery. A synthetic pentasaccharide (fondaparinux), which received an A1 rating in the American College of Chest Physicians recommendations, also is available. As with all treatments, the benefit must be considered against the risk when using these anticoagulants.
引用
收藏
页码:181 / 185
页数:5
相关论文
共 21 条
[1]   Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. [J].
Bauer, KA ;
Eriksson, BI ;
Lassen, MR ;
Turpie, AGG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (18) :1305-1310
[2]   El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis [J].
Brooks, BR ;
Miller, RG ;
Swash, M ;
Munsat, TL .
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS, 2000, 1 (05) :293-299
[3]   Prevention of venous thromboembolism [J].
Clagett, GP ;
Anderson, FA ;
Geerts, W ;
Heit, JA ;
Knudson, M ;
Lieberman, JR ;
Merli, GJ ;
Wheeler, HB .
CHEST, 1998, 114 (05) :531S-560S
[4]   Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery [J].
Colwell, CW ;
Kwong, LM ;
Turpie, AGG ;
Davidson, BL .
JOURNAL OF ARTHROPLASTY, 2006, 21 (01) :36-45
[5]  
Colwell CW, 2005, ORTHOPEDICS, V28, P143
[6]  
COLWELL CW, 1995, CLIN ORTHOP RELAT R, P19
[7]   Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement [J].
Comp, PC ;
Spiro, TE ;
Friedman, RJ ;
Whitsett, TL ;
Johnson, GJ ;
Gardiner, GA ;
Landon, GC ;
Jové, M .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2001, 83A (03) :336-345
[8]   A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty [J].
Freedman, KB ;
Brookenthal, KR ;
Fitzgerald, RH ;
Williams, S ;
Lonner, JH .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2000, 82A (07) :929-938
[9]   Prevention of venous thromboembolism [J].
Geerts, WH ;
Pineo, GF ;
Heit, JA ;
Bergqvist, D ;
Lassen, MR ;
Colwell, CW ;
Ray, JG .
CHEST, 2004, 126 (03) :338S-400S
[10]   Prevention of venous thromboembolism [J].
Geerts, WH ;
Heit, JA ;
Clagett, GP ;
Pineo, GF ;
Colwell, CW ;
Anderson, FA ;
Wheeler, HB .
CHEST, 2001, 119 (01) :132S-175S